98%
921
2 minutes
20
Background: Food prescription programs are gaining interest from funders, policy makers, and healthcare payers as a way to provide value-based care. A small body of research suggests that such programs effectively impact health outcomes; however, the quality of existing studies is variable, and most studies use small samples. This study attempts to address these gaps by utilizing a quasi-experimental design with non-equivalent controls, to evaluate clinical outcomes among participants enrolled in a food prescription program implemented at scale.
Methods: We completed a secondary analysis of participant enrollment and utilization data collected between May 2018 and March 2021, by the Houston Food Bank as part of its multi-institution food prescription program. Enrollment data was obtained from 16 health care partners and redemption data from across 40 food pantries in Houston, Texas. Our objective was to assess if program participation impacted multiple cardio-metabolic markers. Exposure was defined as any visit to a food pantry after receipt of prescription. Linear and logistic regression models were used to estimate change in outcomes by exposure status and number of food pantry visits.
Results: Exposed patients experienced a -0.28% (p = 0.007) greater change in HbA1c than unexposed patients, over six months. Differences across exposure categories were seen with systolic blood pressure (-3.2, p < 0.001) and diastolic blood pressure (-2.5, p = 0.028), over four months. The odds of any decline in HbA1c (OR = 1.06 per visit, p < 0.001) and clinically meaningful decline in HbA1c (OR = 1.04 per visit, p = 0.007) showed a linear association with visit frequency.
Conclusions: Our study of a large food prescription program involving multiple health care and food pantry sites provides robust evidence of a modest decline in HbA1c levels among participants. These results confirm that food prescription programs can continue to be effective at scale, and portend well for institutionalization of such programs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921309 | PMC |
http://dx.doi.org/10.1186/s13104-023-06280-8 | DOI Listing |
Clin Pharmacol Ther
September 2025
School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
This cross-sectional study aims to demonstrate the impact of China's 2015 review and approval reform on the delays in market entry for novel geriatric drugs, as well as the capability of domestic innovation in developing geriatric drugs. We analyzed the novel geriatric drugs approved by the US Food and Drug Administration (FDA) between 2005 and 2024 to assess the drug lags in China by using the EU and Japan as comparators. During this period, the FDA approved a total of 183 novel drugs targeting geriatric diseases, of which 109 were also approved by the NMPA.
View Article and Find Full Text PDFClin Pharmacol Ther
September 2025
Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA.
Industry reports indicate that small biopharmaceutical companies are increasingly launching their own new molecular entities, with first-time companies expected to represent the primary share of blockbuster product launches within the decade. However, company experience may affect the use of Food and Drug Administration (FDA) expedited programs, clinical development times, and FDA review times for new molecular entities and new biologics. Hence, we conducted a cross-sectional study examining all new molecular entity (NME) drug and new biologic approvals by the FDA from 2015 through 2022.
View Article and Find Full Text PDFJ Nutr
September 2025
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
Food is Medicine (FIM) initiatives are food-based nutrition interventions to prevent or manage chronic disease and improve overall health. It is increasingly embraced across healthcare systems, policy makers, and researchers as a promising strategy to address diet-related chronic diseases. Despite this enthusiasm, questions have been raised about whether FIM is overhyped given the still limited evidence.
View Article and Find Full Text PDFCleve Clin J Med
September 2025
Consultant, Department of Internal Medicine, Division of Women's Health, Mayo Clinic, Scottsdale, AZ.
In July 2023, the US Food and Drug Administration approved the first over-the-counter (OTC) daily oral contraceptive pill, Opill (norgestrel). The widespread availability of a daily oral contraceptive pill without a prescription is a major advancement in reproductive health and improves access to safe, effective, affordable contraception. This article outlines the types of OTC contraceptives currently available in the United States, with a focus on OTC norgestrel and its implications for increased accessibility to reproductive healthcare.
View Article and Find Full Text PDFJ Diabetes Res
September 2025
Department of Medicine, Faculty of Medicine, General Sir John Kotelawala Defence University, Colombo, Sri Lanka.
Hypoglycemia has been an often-neglected complication of diabetes therapy. Mild hypoglycemia reduces quality of life, while severe hypoglycemia is life-threatening and can precipitate major cardiovascular and cerebrovascular events. A multicenter cross-sectional study was conducted on hypoglycemia among adults with diabetes attending 19 medical clinics in government hospitals in Sri Lanka using an interviewer-administered questionnaire.
View Article and Find Full Text PDF